주요 내용으로 건너 뛰기

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Recent decades have seen continuing declines in pharmaceutical R&D productivity. Inflation and the COVID-19 pandemic have exacerbated these declines. Model-informed drug development (MIDD) has become an important tool for pharmaceutical companies navigating research and development challenges.

Using advanced mathematical models integrating biology, chemistry, and pharmacology, MIDD helps companies assess drug candidates’ potential, predict drug-drug interactions, and evaluate cost-effectiveness. This technology also helps pharmaceutical firms reduce the risk of expensive clinical development failures. It generates insights across the entire drug development lifecycle, from early drug discovery research to market positioning.

By strategically applying MIDD, pharmaceutical companies can decrease research costs and accelerate bringing lifesaving medicines to market. The technology’s potential extends beyond traditional modeling, offering a comprehensive approach to increasing the productivity of the entire drug development process. Read our article in Forbes to learn more.

Powered by Translations.com GlobalLink Web Software